Bicalutamide is an antiandrogen medication for prostate cancer marketed by AstraZeneca PLC as Casodex with 29 US-DMF and 10 JP-MF. HSCG can provide pilot sample of Bicalutamide as white to off-white powder with above 99.90% purity, and the process validation will be implemented with above 100 KG/batch in 2019. Product Name: Bicalutamide CAS 90357-06-5 Indication: Prostate cancer. Specification: current USP 42 Certificate: Attending PIC/S GMP certificate from TFDA. Non-infringement Description: US4636505 is original patent of Bicalutamide, and already expired on 2004.01.13. Family patents in Japan are J432061B2 and JPS5933250A, and both expired on 2009.05.28. No related patent submitted in Taiwan. In this situation, no infringement concerns arise.
Signup today to claim your Discount. Get Started before it's too late!
